Cannabinoid-1 receptor agonists: a therapeutic option in severe, chronic anorexia nervosa?
نویسنده
چکیده
ISSN 1758-2008 10.2217/NPY.11.50 © 2011 Future Medicine Ltd Neuropsychiatry (2011) 1(5), 467–476 Summary Anorexia nervosa is an enigmatic syndrome and has the highest mortality rate among psychiatric disorders. Nutritional rehabilitation remains both the therapeutic cornerstone and the key challenge, but the evidence for effective therapeutic approaches is still very limited. Cannabinoids have been known and used for centuries, with their antidepressant and appetite-stimulating effects being anecdotally quoted in the literature.
منابع مشابه
Could Dopamine Agonists Aid in Drug Development for Anorexia Nervosa?
Anorexia nervosa is a severe psychiatric disorder most commonly starting during the teenage-years and associated with food refusal and low body weight. Typically there is a loss of menses, intense fear of gaining weight, and an often delusional quality of altered body perception. Anorexia nervosa is also associated with a pattern of high cognitive rigidity, which may contribute to treatment res...
متن کاملEffect of Cannabinoid Receptor Activation on Spreading Depression
Objective(s) The objective of this study was to evaluate the effect of cannabinoid on cortical spreading depression (CSD) in rat brain. Cannabis has been used for centuries for both symptomatic and prophylactic treatment of different types of headaches including migraine. CSD is believed to be a putative neuronal mechanism underlying migraine aura and subsequent pain. Materials and Methods T...
متن کاملOne-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient
BACKGROUND In Japan, growth hormone releasing peptide-2 (GHRP-2) is clinically used as a diagnostic agent for growth hormone secretion deficiency, but the therapeutic application of GHRP-2 has not been studied in anorexia nervosa. GHRP-2 reportedly exhibits agonistic action for ghrelin receptor and increases food intake. METHODS We administered GHRP-2 to a patient with a 20-year history of an...
متن کاملCNS Drugs 2003; 17 (3): 179-202
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179 1. The Endocannabinoid System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181 1.1 Cannabinoid CB1 Receptor Expression . . . . . . . . . . . . . . . ....
متن کاملRole of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.
Cannabis extracts and synthetic cannabinoids are still widely considered illegal substances. Preclinical and clinical studies have suggested that they may result useful to treat diverse diseases, including those related with acute or chronic pain. The discovery of cannabinoid receptors, their endogenous ligands, and the machinery for the synthesis, transport, and degradation of these retrograde...
متن کامل